CN1579385A - New Preparation of Gantaile - Google Patents
New Preparation of Gantaile Download PDFInfo
- Publication number
- CN1579385A CN1579385A CN 03140064 CN03140064A CN1579385A CN 1579385 A CN1579385 A CN 1579385A CN 03140064 CN03140064 CN 03140064 CN 03140064 A CN03140064 A CN 03140064A CN 1579385 A CN1579385 A CN 1579385A
- Authority
- CN
- China
- Prior art keywords
- preparation
- glucuronolatone
- injectable powder
- contain
- props
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to formulation mode of glucurone. The formulation contains 50mg-10g/ampoule glucurone in freeze-dry powder injection solution. The solution can be used for acute and chronic virus hepatitis, hepatocirrhosis, food poisoning and medicine poisoning, it also can be used for arthritis and rheumatism.
Description
● invention field
The present invention is the new preparation way of glucuronolatone.Said preparation is to contain injectable powder and the lyophilized injectable powder that glucuronolatone 50mg-10g/ props up.Said preparation is applicable to acute and chronic viral hepatitis, liver cirrhosis, alimentary toxicosis and drug intoxication clinically, also can be used for arthritis, rheumatism.
● background technology
(Glucuronic acid lactone, Glucurolactone Glucurone) are used for acute and chronic viral hepatitis, liver cirrhosis, alimentary toxicosis and drug intoxication glucuronolatone clinically.Also can be used for arthritis, rheumatism.
The existing tablet of glucuronolatone and two kinds of dosage forms of injection, the tablet specification is every 0.05g, 0.1g.The injection specification is 0.1g/2ml, 0.2g/2ml.Instil every day 1 time among clinical use intravenous drip method: 0.2g～0.4g adding 5%～10% Glucose Liquid 500ml～1000ml.
The glucuronolatone convas tablet has also been developed glucuronolatone injection and compound recipe glucuronolatone injection.Problems such as quality instability, transportation inconvenience appear in glucuronolatone injection in actual use.For improving glucuronolatone stay-in-grade problem in solution, we have developed glucuronolatone injectable powder and lyophilized injectable powder, and these two dosage forms have solved the glucuronolatone injection and have been in quality problem of unstable under the solution state for a long time.Glucuronolatone injectable powder and lyophilized injectable powder exist with pulverulence in production and storage and transport process, and dissolving has improved product stability before use, has also prolonged the shelf-life.
● summary of the invention
The present invention is the new preparation way of glucuronolatone, and said preparation is to contain injectable powder and the lyophilized injectable powder that glucuronolatone 50mg-10g/ props up.Said preparation has solved glucuronolatone quality problem of unstable under solution state, has improved stability of formulation and has prolonged the shelf-life.
● embodiment
Example one: glucuronolatone injectable powder preparation
The glucuronolatone raw material, aseptic process is pressed the operation of powder pin process, the preparation injectable powder.
Example two: glucuronolatone lyophilized injectable powder preparation
The glucuronolatone material solution, after the aseptic filtration, packing also adds the excipient processing, presses the operation of freeze-dried powder process, the preparation lyophilized injectable powder.
Claims (5)
1, new preparation way, said preparation is applicable to acute and chronic viral hepatitis, liver cirrhosis, alimentary toxicosis and drug intoxication clinically, also can be used for arthritis, rheumatism.
2,, it is characterized in that said preparation is to contain the injectable powder that glucuronolatone 50mg-10g/ props up according to the preparation of claim 1.
3,, it is characterized in that said preparation is to contain the lyophilized injectable powder that glucuronolatone 50mg-10g/ props up according to the preparation of claim 1.
4, according to the preparation of claim 2, it is characterized in that said preparation contain one or more adjuvant or and the drug regimen of excipient, wherein contain the injectable powder that glucuronolatone 50mg-10g/ props up.
5, according to the preparation of claim 3, it is characterized in that said preparation contain one or more adjuvant or and the drug regimen of excipient, wherein contain the lyophilized injectable powder that glucuronolatone 50mg-10g/ props up.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03140064 CN1579385A (en) | 2003-08-06 | 2003-08-06 | New Preparation of Gantaile |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03140064 CN1579385A (en) | 2003-08-06 | 2003-08-06 | New Preparation of Gantaile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1579385A true CN1579385A (en) | 2005-02-16 |
Family
ID=34579216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03140064 Pending CN1579385A (en) | 2003-08-06 | 2003-08-06 | New Preparation of Gantaile |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1579385A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1957937B (en) * | 2005-11-04 | 2011-01-12 | 天津天士力集团有限公司 | Dispersion tablet of Glucurolactone, and preparation method |
| CN1957938B (en) * | 2005-11-04 | 2011-07-13 | 天津天士力集团有限公司 | Effervescence tablet of Glucurolactone, and preparation method |
| CN106511365A (en) * | 2016-12-17 | 2017-03-22 | 郑州郑先医药科技有限公司 | Western medicine composition for treating liver cirrhosis |
| CN106620522A (en) * | 2016-12-17 | 2017-05-10 | 郑州郑先医药科技有限公司 | Chinese and western medicine composition for treating liver cirrhosis and preparation method thereof |
-
2003
- 2003-08-06 CN CN 03140064 patent/CN1579385A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1957937B (en) * | 2005-11-04 | 2011-01-12 | 天津天士力集团有限公司 | Dispersion tablet of Glucurolactone, and preparation method |
| CN1957938B (en) * | 2005-11-04 | 2011-07-13 | 天津天士力集团有限公司 | Effervescence tablet of Glucurolactone, and preparation method |
| CN106511365A (en) * | 2016-12-17 | 2017-03-22 | 郑州郑先医药科技有限公司 | Western medicine composition for treating liver cirrhosis |
| CN106620522A (en) * | 2016-12-17 | 2017-05-10 | 郑州郑先医药科技有限公司 | Chinese and western medicine composition for treating liver cirrhosis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI101194B (en) | Process for the preparation of a stabilized lyophilate containing gonadotropin | |
| CN101439036B (en) | Pharmaceutical composition containing 18 kinds of amino acid | |
| US10617649B2 (en) | Preparation method of azacitidine for injection | |
| CN102133199B (en) | Doxofylline lyophilized preparation for injection and preparation method thereof | |
| CN1579385A (en) | New Preparation of Gantaile | |
| CN101152152A (en) | Lgecycline composition for injection and processes for producing same | |
| CN1994461A (en) | Lyophilization process of glutathione for injection | |
| CN102657624B (en) | High optical purity trans-dextro oxaliplatin lyophilized powder injection and preparation method thereof | |
| CN103585018A (en) | New freeze-drying method for reduced glutathione for injection | |
| CN102357081A (en) | Composite fat-soluble vitamin freeze-dried powder injection and preparation method thereof | |
| CN103505424B (en) | Preparation method for bortezomib for injection | |
| CN102512384B (en) | Novel freeze-dried preparation-type protein composition and preparation method thereof | |
| JPH0374643B2 (en) | ||
| CN109044969B (en) | Preparation method of paclitaxel injection | |
| CN1579404A (en) | Novel preparation of glycyrrhizin | |
| CN103720666B (en) | A kind of preparation method of injection bortezomib lyophilized formulations | |
| CN1640409A (en) | High-purity scutellarin injection agent | |
| CN101455646A (en) | Meclofenoxate hydrochloride preparation freeze-drying technique and preparation method thereof | |
| CN101422438A (en) | Composite diisopropyiarmini dichloroacetas freeze-dry preparation without adjuvant and preparation technique thereof | |
| CN108310371B (en) | Blood fat reducing pharmaceutical composition and application thereof | |
| CN103655490A (en) | Idarubicin hydrochloride pharmaceutical composition and preparation method thereof | |
| CN1176658C (en) | Aseptic freeze-dried prostaglandin injection and its preparing method and use | |
| CN109364030A (en) | A kind of injection bortezomib freeze-dried powder and its preparation process | |
| CN102757471A (en) | Novel active cytidine disodium triphosphate compound and pharmaceutical composition thereof | |
| CN1279974C (en) | Technology for preparing capsule of liver cell growth promoting factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |